CanVirex is a spin-off from the Heidelberg University Hospital, founded in 2017 in Basel, Switzerland. The company develops novel immunotherapeutics for the treatment of cancer and has recently committed to using its unique technology to develop a vaccination for protection against COVID-19.
CanVirex and Heidelberg University Hospital have signed a strategic collaboration agreement for the research and clinical development of measles-vectored therapeutics. The Heidelberg University Hospital offers a unique infrastructure for swift clinical translation of our most promising drug candidates. CanVirex has also forged strategic collaborations with key industry partners for GMP manufacturing and commercialization of our products. CanVirex collaborates with the DZIF (German Center for Infection Research) for the development of the COVID-19 vaccine.
Prof. Dr. Dr. Guy Ungerechts, the scientific founder of the company, has dedicated his scientific carreer to explore virus-based cancer therapeutics. Dr. Ungerechts and his scientific team at the Heidelberg University Hospital and the German Cancer Research Center provide extensive technology know-how required for safe and successful clinical development.
- Speck T, Heidbuechel JPW, Veinalde R, Jaeger D, von Kalle C, Ball CR, Ungerechts G, Engeland CE. Targeted BiTE expression by an oncolytic vector augments therapeutic efficacy against solid tumors. Clinical Cancer Research, 2018.
- Veinalde R, Grossardt C, Hartmann L, Bourgeois-Daigneault MC, Bell JC, Jäger D, von Kalle C, Ungerechts G, Engeland CE. Oncolytic measles virus encoding interleukin-12 mediates potent antitumor effects through T cell activation. OncoImmunology, 2017.
- Hajda J, Lehmann M, Krebs O, Kieser M, Geletneky K, Jäger D, Dahm M, Huber B, Schöning T, Sedlaczek O, Stenzinger A, Halama N, Daniel V, Leuchs B, Angelova A, Rommelaere J, Engeland CE, Springfeld C, Ungerechts G. A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol. BMC Cancer, 2017.
- Engeland CE, Grossardt C, Veinalde R, Bossow S, Lutz D, Kaufmann JK, Shevchenko I, Umansky V, Nettelbeck DM, Weichert W, Jäger D, von Kalle C, Ungerechts G. CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy. Mol Ther, 2014.